CLINICAL TRIALS PROFILE FOR TISAGENLECLEUCEL
✉ Email this page to a colleague
All Clinical Trials for tisagenlecleucel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02445248 ↗ | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients | Active, not recruiting | Novartis Pharmaceuticals | Phase 2 | 2015-07-29 | This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | Intrexon Corporation | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | Ziopharm | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | Ziopharm Oncology | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| NCT02529813 ↗ | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Active, not recruiting | M.D. Anderson Cancer Center | Phase 1 | 2015-12-16 | This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled with treatment. Sometimes researchers change the deoxyribonucleic acid (DNA) (genetic material in cells) of donated T-cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient. Injecting modified T-cells made from the patient may help attack cancer cells in patients with advanced B-cell lymphoma or leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tisagenlecleucel
Condition Name
Clinical Trial Locations for tisagenlecleucel
Trials by Country
Clinical Trial Progress for tisagenlecleucel
Clinical Trial Phase
Clinical Trial Sponsors for tisagenlecleucel
Sponsor Name
